Changzhou No.2 People's Hospital
🇨🇳China
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
Phase 1
Not yet recruiting
- Conditions
- Systemic Lupus ErythematosusAutoimmune Hemolytic AnemiaMyasthenia GravisSystemic SclerosisANCA-Associated VasculitisInflammatory MyopathyIgG4-RD
- Interventions
- Biological: universal allogeneic anti-CD19/BCMA CAR T-cells
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT06978738
- Locations
- 🇨🇳
Changzhou No.2 People's Hospital, Changzhou, China
Effectiveness of Multimedia Health Education to Reduce Anxiety in Patients With Vitreous Floaters
Not Applicable
Recruiting
- Conditions
- Vitreous FloatersAnxiety
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06964867
- Locations
- 🇨🇳
the Second People's Hospital of Changzhou, Changzhou, Jiangsu, China
Effectiveness and Safety of 25-Gauge Needle-Assisted Phacoemulsification of Dislocated Intravitreal Lens Nucleus
Completed
- Conditions
- Dislocated LensPars Plana VitrectomyPhacoemulsificationNeedle
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06709378
- Locations
- 🇨🇳
the Second People's Hospital of Changzhou, Changzhou, Jiangsu, China
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: γδ T-PD-1 Ab cells
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06404281
- Locations
- 🇨🇳
Changzhou No.2, Changzhou, China
FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Gastric Cancer
- Interventions
- Combination Product: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
- First Posted Date
- 2024-05-08
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 198
- Registration Number
- NCT06405113
- Locations
- 🇨🇳
Changzhou No.2 People's Hospital, Changzhou, China
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Combination Product: Fecal Microbiota Transplantation (FMT)+chemotherapy+immunotherapy
- First Posted Date
- 2024-05-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT06403111
- Locations
- 🇨🇳
Changzhou No.2 Poeple's Hospital, Changzhou, China
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma
Early Phase 1
Not yet recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Drug: NKG2D Chimeric Antigen Receptor NK Cell Injection
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06379451
- Locations
- 🇨🇳
Changzhou Second People's Hospital, Changzhou, Jiangsu, China
An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia
Early Phase 1
Recruiting
- Conditions
- Thrombocytopenia Alloimmune
- Interventions
- Drug: anti-CD19 CAR NK cells (KN5501)
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06337474
- Locations
- 🇨🇳
Changzhou Second People's Hospital, Changzhou, Jiangsu, China
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03662035
Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer
Phase 2
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2012-03-13
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Changzhou No.2 People's Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT01551641
- Locations
- 🇨🇳
Changzhou No.2 People's Hospital, Changzhou City, Jiangsu, China
© Copyright 2025. All Rights Reserved by MedPath